$0.56 Earnings Per Share Expected for Pfizer Inc. (PFE) This Quarter
Equities analysts forecast that Pfizer Inc. (NYSE:PFE) will report earnings per share of $0.56 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Pfizer’s earnings, with estimates ranging from $0.53 to $0.57. Pfizer reported earnings per share of $0.47 during the same quarter last year, which suggests a positive year-over-year growth rate of 19.1%. The business is expected to issue its next quarterly earnings results on Tuesday, January 30th.
On average, analysts expect that Pfizer will report full year earnings of $2.59 per share for the current financial year, with EPS estimates ranging from $2.57 to $2.60. For the next year, analysts expect that the company will post earnings of $2.74 per share, with EPS estimates ranging from $2.66 to $2.80. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Pfizer.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 EPS.
PFE has been the topic of a number of analyst reports. Cowen set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. Jefferies Group set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Deutsche Bank set a $38.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, October 11th. Finally, Goldman Sachs Group set a $36.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $38.77.
Pfizer (NYSE:PFE) traded down $0.06 during midday trading on Monday, hitting $35.50. The company’s stock had a trading volume of 15,807,773 shares, compared to its average volume of 19,960,639. Pfizer has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a market cap of $212,380.00, a price-to-earnings ratio of 14.25, a PEG ratio of 2.51 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a dividend yield of 3.61%. Pfizer’s payout ratio is 79.01%.
In related news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the stock. Shine Investment Advisory Services Inc. acquired a new position in Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. raised its stake in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth approximately $120,000. Finally, Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer in the first quarter worth approximately $121,000. Institutional investors own 69.89% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/0-56-earnings-per-share-expected-for-pfizer-inc-pfe-this-quarter/1750382.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.